Rafferty Asset Management, LLC Kezar Life Sciences, Inc. Transaction History

Rafferty Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$3.13 - $7.31 $311,832 - $728,273	-99,627 Reduced 28.57%	249,124 $779,000
Q4 2022 Feb 13, 2023	BUY	$6.39 - $8.8 $665,595 - $916,625	104,162 Added 42.59%	348,751 $2.46 Million
Q3 2022 Nov 14, 2022	BUY	$7.99 - $10.75 $1.95 Million - $2.63 Million	244,589 New	244,589 $2.11 Million
Q2 2022 Aug 12, 2022	SELL	$4.58 - $17.13 $629,063 - $2.35 Million	-137,350 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$12.3 - $18.33 $855,182 - $1.27 Million	69,527 Added 102.51%	137,350 $2.28 Million
Q4 2021 Feb 10, 2022	BUY	$7.44 - $16.72 $504,603 - $1.13 Million	67,823 New	67,823 $1.13 Million

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.